110 related articles for article (PubMed ID: 17875783)
1. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
Al-Ejeh F; Darby JM; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5509s-5518s. PubMed ID: 17875783
[TBL] [Abstract][Full Text] [Related]
2. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
Al-Ejeh F; Staudacher AH; Smyth DR; Darby JM; Denoyer D; Tsopelas C; Hicks RJ; Brown MP
J Nucl Med; 2014 May; 55(5):772-9. PubMed ID: 24676755
[TBL] [Abstract][Full Text] [Related]
4. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
Al-Ejeh F; Darby JM; Brown MP
PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Meshram DD; Pike CVS; Coussons PJ
Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
[TBL] [Abstract][Full Text] [Related]
7. The human La (SS-B) autoantigen interacts with DDX15/hPrp43, a putative DEAH-box RNA helicase.
Fouraux MA; Kolkman MJ; Van der Heijden A; De Jong AS; Van Venrooij WJ; Pruijn GJ
RNA; 2002 Nov; 8(11):1428-43. PubMed ID: 12458796
[TBL] [Abstract][Full Text] [Related]
8. La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis.
Ayukawa K; Taniguchi S; Masumoto J; Hashimoto S; Sarvotham H; Hara A; Aoyama T; Sagara J
J Biol Chem; 2000 Nov; 275(44):34465-70. PubMed ID: 10913436
[TBL] [Abstract][Full Text] [Related]
9. Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
Stamnaes J; Iversen R; du Pré MF; Chen X; Sollid LM
PLoS One; 2015; 10(8):e0134922. PubMed ID: 26244572
[TBL] [Abstract][Full Text] [Related]
10. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
[TBL] [Abstract][Full Text] [Related]
11. A cell surface antigen (BAL) defined by a mouse monoclonal antibody inducing apoptosis in a human lymphocytic leukemia cell line.
Wallén-Ohman M; Borrebaeck CA
Int J Cancer; 1994 May; 57(4):544-52. PubMed ID: 8181858
[TBL] [Abstract][Full Text] [Related]
12. Detection of in situ activation of transglutaminase during apoptosis: correlation with the cell cycle phase by multiparameter flow and laser scanning cytometry.
Grabarek J; Ardelt B; Kunicki J; Darzynkiewicz Z
Cytometry; 2002 Oct; 49(2):83-9. PubMed ID: 12357464
[TBL] [Abstract][Full Text] [Related]
13. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the autoantigen La (SS-B) as a dsRNA unwinding enzyme.
Hühn P; Pruijn GJ; van Venrooij WJ; Bachmann M
Nucleic Acids Res; 1997 Jan; 25(2):410-6. PubMed ID: 9016572
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
16. The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
Staudacher AH; Al-Ejeh F; Fraser CK; Darby JM; Roder DM; Ruszkiewicz A; Manavis J; Brown MP
EJNMMI Res; 2014 Jan; 4(1):2. PubMed ID: 24387284
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609.
Pörn-Ares MI; Chow SC; Slotte JP; Orrenius S
Exp Cell Res; 1997 Aug; 235(1):48-54. PubMed ID: 9281351
[TBL] [Abstract][Full Text] [Related]
19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
20. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
